In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

About Myasthenia Gravis. Myasthenia Gravis (MG) is a rare neurological disorder that severely impairs muscle movement and can lead to life-threatening complications.

Good evidence that intravenous immunoglobulin treatment within the first 10 days of symptoms reduces coronary artery abnormalities (heart damage) in children with Kawasaki disease. Kawasaki disease is ...

Abstract. Background Comorbid autoimmune disorders affect approximately 0.2% of the population.A second autoimmune disease occurs in up to 15% of myasthenia gravis (MG) patients. Objective To evaluate ...

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, ... Intravenous immunoglobulin and plasma exchange have a similar effect, ...

Background Myasthenia Gravis (MG) is an autoimmune disorder presenting with fatigable muscle weakness leading to potential respiratory distress. Clinical management aims to improve patient quality of ...

Myasthenia gravis affects both men and women and occurs across all races and ... Steroids were used in 57.7% of patients, IVIG in 10.7%, plasmapheresis in 5.5%, and thymectomy in 5.0%. Steroid ...

People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...

The NHS webpage on myasthenia gravis may be a good place to find out more. These organisations can give you advice and support: Myaware, 01332 290 219; Muscular Dystrophy UK, 0800 652 6352; You can ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...